A detailed history of Nuveen Asset Management, LLC transactions in Legend Biotech Corp stock. As of the latest transaction made, Nuveen Asset Management, LLC holds 104,886 shares of LEGN stock, worth $3.44 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
104,886
Previous 100,586 4.27%
Holding current value
$3.44 Million
Previous $4.45 Million 14.75%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$43.55 - $59.88 $187,265 - $257,484
4,300 Added 4.27%
104,886 $5.11 Million
Q2 2024

Aug 09, 2024

SELL
$39.5 - $57.22 $59,250 - $85,830
-1,500 Reduced 1.47%
100,586 $4.45 Million
Q1 2024

May 13, 2024

SELL
$55.06 - $69.99 $3.11 Million - $3.95 Million
-56,485 Reduced 35.62%
102,086 $5.73 Million
Q4 2023

Feb 14, 2024

BUY
$57.25 - $69.74 $1.12 Million - $1.37 Million
19,600 Added 14.1%
158,571 $9.54 Million
Q3 2023

Nov 14, 2023

BUY
$63.16 - $76.5 $1.37 Million - $1.66 Million
21,666 Added 18.47%
138,971 $9.33 Million
Q2 2023

Aug 14, 2023

SELL
$46.28 - $75.01 $35,450 - $57,457
-766 Reduced 0.65%
117,305 $8.1 Million
Q1 2023

May 15, 2023

BUY
$43.42 - $57.37 $716,430 - $946,605
16,500 Added 16.24%
118,071 $5.69 Million
Q4 2022

Feb 14, 2023

SELL
$38.8 - $55.46 $65,960 - $94,282
-1,700 Reduced 1.65%
101,571 $5.07 Million
Q3 2022

Nov 14, 2022

BUY
$38.15 - $57.1 $255,605 - $382,570
6,700 Added 6.94%
103,271 $4.21 Million
Q2 2022

Aug 15, 2022

SELL
$33.54 - $55.0 $243,131 - $398,695
-7,249 Reduced 6.98%
96,571 $5.31 Million
Q1 2022

May 16, 2022

BUY
$31.02 - $48.18 $328,812 - $510,708
10,600 Added 11.37%
103,820 $3.77 Million
Q4 2021

Feb 14, 2022

BUY
$41.14 - $56.98 $3.84 Million - $5.31 Million
93,220 New
93,220 $4.35 Million

Others Institutions Holding LEGN

About Legend Biotech Corp


  • Ticker LEGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 167,403,008
  • Market Cap $5.49B
  • Description
  • Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery and development of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multipl...
More about LEGN
Track This Portfolio

Track Nuveen Asset Management, LLC Portfolio

Follow Nuveen Asset Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Nuveen Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Nuveen Asset Management, LLC with notifications on news.